Avidity Partners Management’s AC Immune ACIU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-825,000
Closed -$3.29M 82
2024
Q2
$3.29M Sell
825,000
-3,645,000
-82% -$12.1M 0.14% 78
2024
Q1
$13.2M Buy
4,470,000
+920
+0% +$3.3K 0.43% 64
2023
Q4
$22.3M Buy
4,469,080
+1,499,280
+50% +$4.82M 0.81% 47
2023
Q3
$8.46M Buy
2,969,800
+66,522
+2% +$203K 0.34% 68
2023
Q2
$8.58M Buy
2,903,278
+2,577,878
+792% +$5.63M 0.3% 75
2023
Q1
$761K Hold
325,400
0.03% 81
2022
Q4
$664K Buy
325,400
+50,524
+18% +$130K 0.01% 82
2022
Q3
$869K Buy
+274,876
New +$866K 0.02% 91
2021
Q4
Sell
-1,739,600
Closed -$11.7M 98
2021
Q3
$11.7M Buy
1,739,600
+155,600
+10% +$1.11M 0.26% 66
2021
Q2
$12.6M Buy
+1,584,000
New +$10.9M 0.34% 64
2020
Q4
Sell
-1,550,000
Closed -$7.56M 97
2020
Q3
$7.56M Buy
+1,550,000
New +$11.1M 0.35% 51

Other funds holding ACIU

Avidity Partners Management's ACIU Position: Q3 2024 in Review

Avidity Partners Management sold out of AC Immune (ACIU) in Q3 2024, closing a stake of 825,000 shares — an estimated $3.29M sold.

Avidity Partners Management first reported a position in ACIU in Q3 2020 and held it in 11 quarters. The position peaked at $22.3M in Q4 2023. 43 funds tracked by Wall St. Rank hold ACIU as of Q3 2024.

  • Avidity Partners Management reported no remaining AC Immune position as of Q3 2024 after selling out during the quarter.
  • Avidity Partners Management sold 825,000 AC Immune shares in Q3 2024, an estimated $3.29M.
  • Avidity Partners Management first reported a position in AC Immune in Q3 2020 and held it in 11 quarters.
  • Avidity Partners Management's AC Immune position peaked at $22.3M in Q4 2023.
  • 43 funds tracked by Wall St. Rank held AC Immune as of Q3 2024.

Based on Avidity Partners Management's 13F filing for Q3 2024, filed 14 Nov 2024.